Best Antibiotic Treatment for Skin Abscesses
For skin abscesses, incision and drainage is the primary treatment, with antibiotics indicated only when there are systemic signs of infection, significant surrounding cellulitis, or in immunocompromised patients. 1
Primary Management Approach
Incision and drainage (I&D) is the cornerstone of treatment for all skin abscesses 1
- Small, simple abscesses may require I&D alone without antibiotics
- Ensure complete drainage of all loculations
Antibiotic therapy indications (when to add antibiotics after I&D):
Antibiotic Selection
When antibiotics are indicated, the following options are recommended:
First-line options:
Alternative options:
- Doxycycline: 100 mg PO BID for 5-10 days 1, 2
- Effective against MRSA
- Limited activity against streptococci
- Not recommended for children <8 years or pregnant women 2
Special Considerations
MRSA coverage:
- An antibiotic active against MRSA is recommended for patients with:
- Markedly impaired host defenses
- SIRS
- Known MRSA colonization or previous MRSA infection 1
- Areas with high MRSA prevalence
- An antibiotic active against MRSA is recommended for patients with:
Recurrent abscesses:
Duration of therapy:
Treatment Algorithm
For simple, small abscesses without systemic signs:
- I&D alone is sufficient 1
- No antibiotics needed
For abscesses with systemic signs, significant cellulitis, or in immunocompromised patients:
For complex or recurrent abscesses:
- Perform I&D
- Obtain cultures
- Start empiric antibiotic therapy
- Adjust antibiotics based on culture results
- Consider decolonization protocol 1
Common Pitfalls to Avoid
- Prescribing antibiotics for all abscesses - most simple abscesses require only I&D 1
- Inadequate drainage - ensure complete evacuation of all purulent material
- Using TMP-SMX as a single agent for cellulitis - it has limited activity against streptococci 1
- Not considering MRSA coverage in areas with high prevalence
- Failing to search for underlying causes in recurrent abscesses 1
Recent evidence from a high-quality randomized controlled trial shows that for smaller abscesses (≤5 cm), both TMP-SMX and clindamycin in conjunction with I&D improve outcomes compared to I&D alone, with clinical cure rates of 81.7% and 83.1% respectively versus 68.9% for placebo 3. However, this benefit must be weighed against the potential for adverse effects.